UCLA doctors and researchers have been pioneers in immunotherapy and continue to be at the forefront of cancer treatments and discoveries in precision health.
UCLA Health is one of the first centers in the nation to offer CAR T-cell therapy for all FDA approved indications and many clinical trials as well. Our physicians, along with researchers and clinicians from the UCLA Jonsson Comprehensive Cancer Center, hold an international reputation for providing the best in experimental and traditional cancer treatments and expertly guiding the next generation of medical research.
For more information, please call one of the following numbers and let our staff know that you are calling about CAR T-cell therapy:
Patients 1-888-ONC-UCLA (888-662-8252)
Chimeric antigen receptor (CAR) T-cell therapy is a type of immunotherapy recently approved by the U.S. Food and Drug Administration (FDA). The FDA has approved:
UCLA Health is now able to use CAR T cells for all current FDA-approved indications, in addition to the many CAR clinical trials available at UCLA Health. As with every type of cancer treatment, there are potential side effects. UCLA clinicians and staff participated in the clinical trials, prior to FDA approval, and have experience and expertise in the management of these risks.
Immunotherapy is one of the most recent breakthroughs that enable doctors to treat certain types of cancer. Researchers, including those at UCLA, have discovered ways to make a patient’s own immune system fight cancer cells.
Immunotherapy is a new treatment category that is different from established cancer treatments such as chemotherapy, radiation, surgery and transplant. At UCLA Health, clinical experts in every type of cancer therapy integrate the best treatment strategies, including immunotherapy, to help develop the best treatment plans for each patient.
CAR T-cells are genetically altered immune cells designed to attack cancer cells. T cells (central components of the immune system) are taken from a patient’s bloodstream, modified to bind to a specific protein found on cancer cells and then placed back into the patient’s system, where the modified T cells can attack the cancer cells. The major difference to established treatments is that this approach enables a patient’s own immune system to fight his or her cancer cells.
Highlights of our program include:
Physicians 1-844-4UCLADR (844-482-5237)
For information about open clinical trials facilitated by UCLA, contact the Clinical Trials Hotline at 888-798-0719.
For one early adopter, CAR T therapy means 18 months cancer-free and counting >
Sarah Larson, MD | UCLA Community Cancer Care
Satiro de Oliveira, MD | UCLA Pediatric Hematology Oncology